Versartis, Inc. (VSAR) To Hold Conference Call To Discuss Six Month VRS-317 Phase 2a VERTICAL Clinical Trial Results
6/9/2014 9:01:09 AM
MENLO PARK, Calif., June 9, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Monday, June 23, 2014 at 5:00 p.m. EDT (4:00 p.m. CDT).
Help employers find you! Check out all the jobs and post your resume.
comments powered by